Hargreave Hale AIM VCT led the financing round to help accelerate the company platform and expand into new disease areas.
"The close of our Series A round marks the 'end of the beginning' and the start of a new chapter for Qureight, as we turn our focus to developing our platform and creating products in new disease areas. Our mission to extend the lives of lung and heart disease patients will be bolstered by the invaluable expertise of our new board and new senior team members, and we are looking forward to adding to our strategic biopharma collaborations."
The pre-series b round was led by Samaipata and Stage 2 Capital to support client acquisition and technology development.
"With the cost of failed hires estimated to be three times their annual salary, Veremark’s efficient solution to background screening is helping businesses make fully informed hiring decisions. Despite a global slow down in recruitment, the company has continued to deliver exceptional growth due to the value it brings to customers. We are excited to continue backing Veremark’s remarkable growth journey as it continues to redefine workplace compliance and screening."
The funding comes from the UK athlete-led venture capital firm to connect sports figures with the ticketing platform.
"This investment from The Players Fund signifies an exciting new chapter for Seat Unique as we expand our reach to wider audiences. One of the key advantages of this partnership is the access to The Players Fund’s extensive athlete network. With their support, we can work closely with renowned athletes to increase brand visibility and promote the unique experiences available on our platform."
